Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (15215)	1/11/2005 9:18:17 PM
From: former_pgs	Read Replies (2) \| Respond to of 52153

With the blended monthly data, the company can figure out, with pretty good precision, the minimum overall median survival for the trial as well as the minimum 1 year survival %. Without any data, the company would have no idea where the blended median or 1 year survival are heading, making it impossible for them to make bullish / foolish comments in public. Foolish comments reflect poorly on the industry in general and have the possibility to mislead novice investors. In my opinion, the possible loss in credibility and investor confidence outweighs the value to be gained from publicizing blended / blinded data. And a thank you to my crack proofreaders. The prior post should have used the word "remunerate" instead of the imaginary word "renumerate". Irregardless, i think the gist was clear.